Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Patients

LN Lars Ny
HJ Henrik Jespersen
JK Joakim Karlsson
SA Samuel Alsén
SF Stefan Filges
CA Charlotta All-Eriksson
BA Bengt Andersson
AC Ana Carneiro
HH Hildur Helgadottir
ML Max Levin
IL Ingrid Ljuslinder
RB Roger Olofsson Bagge
VS Vasu R. Sah
US Ulrika Stierner
AS Anders Ståhlberg
GU Gustav Ullenhag
LN Lisa M. Nilsson
JN Jonas A. Nilsson
request Request a Protocol
ask Ask a question
Favorite

Eligible patients were aged ≥18 years and had histologically or cytologically confirmed metastatic UM; measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as per RECIST 1.1 criteria; ECOG performance status 0–1; and could have received any number of prior therapies (including none), with the exception of anticancer immunotherapy. Key exclusion criteria were active brain metastases, active autoimmune disease, immunodeficiency or treatment with systemic corticosteroids, previous treatment with anticancer immunotherapy, use of other investigational drugs within four weeks before study drug administration, and life expectancy of less than three months. The first patient was enrolled on 21 February 2018 and the last patient was enrolled on 21 December 2018.

Copyright and License information: The Author(s) ©2021
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A